Needham analyst Ami Fadia maintains Avadel Pharmaceuticals (NASDAQ:AVDL) with a Buy and lowers the price target from $16 to $15.
Susquehanna Maintains Neutral on Power Integrations, Lowers Price Target to $95
Susquehanna analyst Christopher Rolland maintains Power Integrations (NASDAQ:POWI) with a Neutral and lowers the price target from $105 to $95.